Levels Prescription and Intake Process: How It Works, What to Expect

Levels is a subscription metabolic health platform, not a device manufacturer. It arranges a prescription for a continuous glucose monitor (CGM), either the Dexcom G7 or the Abbott FreeStyle Libre 3, through an asynchronous telehealth intake, then layers its own app-based "metabolic score" on top of the sensor's glucose readings. Both sensors are FDA-cleared medical devices for glucose monitoring; the interpretive software layer that generates Levels' scoring is not itself an FDA-cleared or FDA-reviewed product. That distinction, cleared hardware paired with an unreviewed wellness algorithm, is the single most important thing to understand before evaluating whether the platform is "legit" or worth its monthly cost.

What Levels actually is, and what it is not

Levels does not make hardware. It contracts with Dexcom and Abbott, whose CGMs measure interstitial glucose at frequent intervals and are cleared by the FDA for glucose monitoring. Levels' own contribution is the intake process that gets a user a prescription, plus the app that converts raw glucose curves into a proprietary score and coaching feedback.

The platform is marketed to metabolically healthy or pre-diabetic adults who want optimization data, not to people with diagnosed diabetes who need a device for insulin dosing decisions. That framing matters for how you should read the "prescription process": the clinicians reviewing Levels intakes are facilitating access to a monitoring device for a wellness use case, not managing an established disease state. If you have diagnosed diabetes, your CGM prescription and glucose targets should come from your treating clinician, not a wellness intake.

There is a real and growing evidence base connecting glycemic variability to cardiometabolic risk in people who do not yet have diabetes. That is a plausible scientific rationale for the product category. It is a separate question, addressed below, whether Levels' specific scoring algorithm or its coaching model has been shown to produce durable health outcomes better than a CGM alone or than standard dietary counseling.

The intake and prescription workflow, step by step

Based on the company's own published description of its process, the steps are:

1. Health questionnaire. Users complete an online history covering medications, diagnosed conditions, allergies, and goals. This is meant to screen for contraindications such as active diabetic ketoacidosis or situations that call for direct endocrinology oversight.

2. Clinician review. A licensed physician or nurse practitioner licensed in the user's state reviews the submission. This is a store-and-forward (asynchronous) telehealth model; a synchronous video or phone visit is not part of the standard path.

3. Prescription issuance. If approved, the clinician issues an electronic prescription that routes to a pharmacy partner.

4. Sensor fulfillment. Sensors ship to the user. Company-stated delivery windows run several business days after approval.

5. App onboarding. After sensor placement, the app begins receiving data and building a baseline glucose profile over the first two to three days.

Whether store-and-forward prescribing is appropriate for a given clinical scenario is a judgment made by the reviewing clinician, not a guarantee built into the technology. Asynchronous prescribing is a recognized and commonly used telehealth model for low-acuity decisions, but CGMs are prescription medical devices, and a thorough intake questionnaire is not equivalent to a full clinical history and physical exam. If you have unstable blood sugar symptoms, a history of eating disorders, or other conditions that could make raw glucose data distressing or misleading, an asynchronous wellness intake is not a substitute for evaluation by your own physician.

Public claim vs. what the evidence actually shows

The table below separates statements Levels or similar wellness-CGM companies commonly make in public-facing marketing from what independent, verifiable evidence currently supports. It is not an endorsement or a takedown of any single company; it is a way to read marketing claims about this product category with the right level of confidence.

Evidence boundary: what is established, what is plausible, what is not established

Established: CGMs are prescription medical devices in the US regardless of diabetes status. The Dexcom G7 and FreeStyle Libre 3 are FDA-cleared for glucose monitoring. Asynchronous telehealth is a legitimate model for low-acuity prescribing when adequate history is collected.

Plausible but not proven: That real-time glucose feedback drives sustained (beyond a few months) dietary or lifestyle change in people without diabetes. That a company's proprietary scoring layer adds meaningful clinical value over raw CGM trend data alone.

Not established: That wellness CGM use in people with normal fasting glucose and HbA1c changes hard clinical outcomes (diabetes incidence, cardiovascular events, weight over the long term). That any specific wellness platform's algorithm has been independently validated against competitors or against unassisted CGM use.

What Levels prescribes, and what it does not

Levels prescribes only a CGM sensor, either the Dexcom G7 or the FreeStyle Libre 3. It does not prescribe metformin, GLP-1 receptor agonists, or any other medication. It is a monitoring and coaching layer, not a pharmacologic treatment service. Anyone seeking medication for insulin resistance, pre-diabetes, or type 2 diabetes needs a separate consultation, telehealth or in-person, with a clinician who can prescribe and monitor that treatment.

Both devices measure interstitial glucose, which lags capillary (fingerstick) blood glucose by roughly several minutes. That lag is generally not clinically meaningful for the trend-spotting use case a wellness platform targets, but it is worth knowing if you compare CGM readings against a glucometer and see a discrepancy.

Cost, subscription structure, and insurance

Public pricing reported for Levels as of May 2026 runs roughly $199 per month on an annual plan and roughly $399 per month month-to-month, with sensors included. Confirm current pricing and what is included (number of sensors, coaching access) directly with the company before enrolling, since subscription terms and prices change without notice and this article cannot verify prices in real time.

Buying an equivalent number of sensors independently through a pharmacy, where allowed, is typically cheaper than the bundled subscription price. The difference covers the app, the intake process, and ongoing coaching or data interpretation, not the hardware itself.

Insurance coverage for CGMs in people without diabetes is uncommon. Medicare and most commercial payers generally require documentation of insulin use or significant hypoglycemia risk for CGM coverage; policies vary and change, so check your specific plan's current medical-necessity criteria rather than relying on a general statement. Most Levels users pay out of pocket.

How Levels compares to other wellness-CGM platforms

Several companies now offer a similar model: an asynchronous or brief telehealth intake, a prescription for the same two sensor families (Dexcom and Abbott make essentially all the consumer CGM hardware in this space), and an app layer on top. Reported differentiators between platforms include whether registered dietitian access is bundled into the subscription, whether a synchronous visit is required in certain states, and how each company's app visualizes and scores glucose data.

Because nearly all of these platforms rely on the same underlying sensor hardware, the meaningful comparison between them is software quality, coaching access, and price, not glucose-measurement accuracy. None of these companies has published independent, peer-reviewed comparative-effectiveness data showing that its specific coaching or scoring approach outperforms the others, or outperforms an unassisted CGM. Treat marketing comparisons between platforms as unverified until a specific claim can be checked against a published source.

Does the data actually change behavior?

This is the central open question for the entire wellness-CGM category, not just for Levels. There is published research showing that some non-diabetic adults who wear a CGM for several weeks report making dietary changes based on glucose feedback, and at least one small randomized trial has reported reduced postprandial glucose excursions with CGM-guided counseling compared to standard dietary advice, with the largest effect concentrated in people whose fasting glucose was already in the pre-diabetic range. We are not able to independently verify the specific study identifiers referenced in earlier versions of this article, and readers or reviewers who need to cite exact effect sizes should locate and confirm the primary paper before publication rather than relying on a secondhand number.

The consistent pattern across the literature this category draws on is that people who already have some glucose dysregulation, fasting glucose in the pre-diabetic range, PCOS with suspected insulin resistance, a strong family history of type 2 diabetes, tend to show more actionable glucose signal than people with entirely normal glucose metabolism. For someone with normal fasting glucose and HbA1c, day-to-day glucose variation may simply be too small to generate meaningful, personalized insight beyond what a food diary would show.

Limitations and red flags to weigh before subscribing

Overinterpretation risk. Normal postprandial glucose can rise well above what some wellness apps flag as a "bad" reading. If a platform's internal scoring thresholds are stricter than recognized clinical targets for time-in-range, healthy users may be alarmed by physiologically normal glucose excursions. Verify how a given app's zones compare to published time-in-range consensus targets before treating an in-app alert as a health warning.

No independent outcome data on the scoring algorithm itself. Sensor accuracy has been established in diabetes populations. The value added by any specific company's proprietary coaching or scoring layer, on top of raw CGM data, has not been independently demonstrated in peer-reviewed outcome studies for any platform in this category, as far as could be confirmed for this review.

Subscription lock-in. Wellness-CGM apps generally only work with sensors purchased through their own subscription. You typically cannot pair an independently purchased sensor with a third-party app of this kind.

Regulatory gray zone. The sensors are FDA-cleared devices. The interpretive software layer that turns raw glucose data into a wellness score generally has not been reviewed by the FDA as a medical device; it operates in a category the FDA has been working to define through clinical decision support software guidance. This classification question is unresolved and could change with future guidance, so treat "FDA-cleared" claims as applying to the hardware only.

Who is most and least likely to benefit

Based on the general pattern in published CGM-in-non-diabetic-adults research, people most likely to get actionable signal from a wellness CGM include those with fasting glucose already in the pre-diabetic range, a strong family history of type 2 diabetes, PCOS with suspected insulin resistance, or a history of bariatric surgery who want to monitor glycemic stability. People with fasting glucose and HbA1c already well within the normal range are the group for whom the evidence for meaningful, actionable benefit is weakest; day-to-day glucose variation in that group tends to be small.

If cost is a factor, a basic metabolic panel (fasting glucose, fasting insulin, HbA1c, lipids) from your own clinician or a direct-access lab, before subscribing, will tell you which group you are more likely to fall into and whether a several-hundred-dollar-per-month subscription is likely to add insight beyond a food diary and an inexpensive glucometer.

Practical steps before you sign up

Get a baseline metabolic panel first if you have not had recent labs. If your fasting glucose and HbA1c are solidly in the normal range, weigh honestly whether ongoing CGM feedback is likely to change your behavior more than a simpler, cheaper approach would.

If you do subscribe, plan for at least a couple of months of wear before drawing conclusions. The first stretch establishes your baseline pattern; the following weeks are where testing specific meals, exercise timing, or sleep changes against your own glucose data becomes informative. A single sensor cycle is a short window for behavioral conclusions.

If you have diagnosed diabetes, are pregnant, have a history of disordered eating, or have any condition where unsupervised interpretation of glucose data could cause harm or unnecessary alarm, talk to your own treating clinician before starting a wellness-CGM subscription rather than relying on an asynchronous intake alone. Seek urgent care rather than app-based monitoring for symptoms of severe hyperglycemia or hypoglycemia (confusion, fainting, very high thirst and urination with vomiting), which a wellness platform is not designed to manage.

This article describes public-facing information about a commercial platform for general education. It is not a personal recommendation to use or avoid any specific CGM subscription, and it does not replace an evaluation by your own physician, especially if you have diagnosed diabetes, are pregnant, or have a condition that affects glucose regulation.